A Comprehensive Analysis of Ribonucleotide Reductase Subunit M2 for Carcinogenesis in Pan-cancer

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Apr 18

PMID 38635758

Authors

Yong Wang

Rong Chen

Jing Zhang

Peng Zeng

Affiliations

Soon will be listed here.

Abstract

Background: Although there is evidence that ribonucleotide reductase subunit M2 (RRM2) is associated with numerous cancers, pan-cancer analysis has seldom been conducted. This study aimed to explore the potential carcinogenesis of RRM2 in pan-cancer using datasets from The Cancer Genome Atlas (TCGA).

Methods: Data from the UCSC Xena database were analyzed to investigate the differential expression of RRM2 across multiple cancer types. Clinical data such as age, race, sex, tumor stage, and status were acquired to analyze the influence of RRM2 on the clinical characteristics of the patients. The role of RRM2 in the onset and progression of multiple cancers has been examined in terms of genetic changes at the molecular level, including tumor mutational burden (TMB), microsatellite instability (MSI), biological pathway changes, and the immune microenvironment.

Results: RRM2 was highly expressed in most cancers, and there was an obvious correlation between RRM2 expression and patient prognosis. RRM2 expression is associated with the infiltration of diverse immune and endothelial cells, immune checkpoints, tumor mutational burden (TMB), and microsatellite instability (MSI). Moreover, the cell cycle is involved in the functional mechanisms of RRM2.

Conclusions: Our pan-cancer study provides a comprehensive understanding of the carcinogenesis of RRM2 in various tumors.

References

Ohmura S, Marchetto A, Orth M, Li J, Jabar S, Ranft A . Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma. Mol Cancer. 2021; 20(1):97. PMC: 8314608. DOI: 10.1186/s12943-021-01393-9. View

Ma C, Luo H, Cao J, Gao C, Fa X, Wang G . Independent prognostic implications of in lung adenocarcinoma. J Cancer. 2020; 11(23):7009-7022. PMC: 7592001. DOI: 10.7150/jca.47895. View

Li Z, Zheng Z, Wei Z, Zhang L, Li F, Lin L . Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment. Theranostics. 2019; 9(25):7648-7665. PMC: 6831462. DOI: 10.7150/thno.36585. View

Bardou P, Mariette J, Escudie F, Djemiel C, Klopp C . jvenn: an interactive Venn diagram viewer. BMC Bioinformatics. 2014; 15:293. PMC: 4261873. DOI: 10.1186/1471-2105-15-293. View

Aimiuwu J, Wang H, Chen P, Xie Z, Wang J, Liu S . RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood. 2012; 119(22):5229-38. PMC: 3369613. DOI: 10.1182/blood-2011-11-382226. View

Sun H, Yang B, Zhang H, Song J, Zhang Y, Xing J . RRM2 is a potential prognostic biomarker with functional significance in glioma. Int J Biol Sci. 2019; 15(3):533-543. PMC: 6367584. DOI: 10.7150/ijbs.30114. View

Granieri L, Marocchi F, Melixetian M, Mohammadi N, Nicoli P, Cuomo A . Targeting the USP7/RRM2 axis drives senescence and sensitizes melanoma cells to HDAC/LSD1 inhibitors. Cell Rep. 2022; 40(12):111396. DOI: 10.1016/j.celrep.2022.111396. View

Shu Z, Li Z, Huang H, Chen Y, Fan J, Yu L . Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition. Oncogene. 2020; 39(35):5721-5733. DOI: 10.1038/s41388-020-01403-y. View

Weber J . Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol. 2010; 37(5):430-9. DOI: 10.1053/j.seminoncol.2010.09.005. View

10.

Pages F, Galon J, Dieu-Nosjean M, Tartour E, Sautes-Fridman C, Fridman W . Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene. 2009; 29(8):1093-102. DOI: 10.1038/onc.2009.416. View

11.

Tabbal H, Septier A, Mathieu M, Drelon C, Rodriguez S, Djari C . EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness. Br J Cancer. 2019; 121(5):384-394. PMC: 6738105. DOI: 10.1038/s41416-019-0538-y. View

12.

Gandhi M, Gross M, Holler J, Coggins S, Patil N, Leupold J . The lncRNA lincNMR regulates nucleotide metabolism via a YBX1 - RRM2 axis in cancer. Nat Commun. 2020; 11(1):3214. PMC: 7316977. DOI: 10.1038/s41467-020-17007-9. View

13.

Mazzu Y, Armenia J, Chakraborty G, Yoshikawa Y, Coggins S, Nandakumar S . A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019; 25(14):4480-4492. PMC: 6820162. DOI: 10.1158/1078-0432.CCR-18-4046. View

14.

Petitprez F, Meylan M, De Reynies A, Sautes-Fridman C, Fridman W . The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Front Immunol. 2020; 11:784. PMC: 7221158. DOI: 10.3389/fimmu.2020.00784. View

15.

Grolmusz V, Karaszi K, Micsik T, Toth E, Meszaros K, Karvaly G . Cell cycle dependent RRM2 may serve as proliferation marker and pharmaceutical target in adrenocortical cancer. Am J Cancer Res. 2016; 6(9):2041-2053. PMC: 5043113. View

16.

Osipov A, Saung M, Zheng L, Murphy A . Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. J Immunother Cancer. 2019; 7(1):224. PMC: 6704558. DOI: 10.1186/s40425-019-0667-0. View

17.

Zheng S, Wang X, Weng Y, Jin X, Ji J, Guo L . siRNA Knockdown of RRM2 Effectively Suppressed Pancreatic Tumor Growth Alone or Synergistically with Doxorubicin. Mol Ther Nucleic Acids. 2018; 12:805-816. PMC: 6118156. DOI: 10.1016/j.omtn.2018.08.003. View

18.

Huang N, Guo W, Ren K, Li W, Jiang Y, Sun J . LncRNA AFAP1-AS1 Supresses miR-139-5p and Promotes Cell Proliferation and Chemotherapy Resistance of Non-small Cell Lung Cancer by Competitively Upregulating RRM2. Front Oncol. 2019; 9:1103. PMC: 6817562. DOI: 10.3389/fonc.2019.01103. View

19.

Jin C, Du L, Nuerlan A, Wang X, Yang Y, Guo R . High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma. Aging (Albany NY). 2021; 13(3):3518-3535. PMC: 7906179. DOI: 10.18632/aging.202292. View

20.

Ritchie M, Phipson B, Wu D, Hu Y, Law C, Shi W . limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7):e47. PMC: 4402510. DOI: 10.1093/nar/gkv007. View